

AD_____

AWARD NUMBER: W81XWH-04-1-0046

TITLE: Identify the impact of TGF- β signaling on the stroma in the progression of prostate cancer

PRINCIPAL INVESTIGATOR: Neil A. Bhowmick, Ph.D.

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center
Nashville, Tennessee 37203-6917

REPORT DATE: March 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) March 2006		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 Mar 05 – 28 Feb 06	
4. TITLE AND SUBTITLE Identify the impact of TGF- β signaling on the stroma in the progression of prostate cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0046	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Neil A. Bhowmick, Ph.D. E-Mail: neil.bhowmick@vanderbilt.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vanderbilt University Medical Center Nashville, Tennessee 37203-6917				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT As a result of androgen ablation TGF- β 1 expression levels transiently elevate and regression of benign prostate hyperplasia as well as prostate cancer cells for the most part occur. Better understanding of prostate androgen responsiveness is critical in understanding and ultimately combating androgen-non-responsive prostate cancer. Studying the conditional TGF- β type II receptor fibroblast knockout mouse model we developed (F β KO), we found that TGF- β signaling in the prostate stromal fibroblasts regulate both stromal and epithelial differentiation in the prostate. As proposed we attempted to develop mice that are stromally knocked out for TGF- β signaling and express the large T antigen in the prostate epithelia, but was unsuccessful. Thus we made tissue recombinants of prostatic epithelia with F β KO stromal cells. This resulted in the development of poorly differentiated adenocarcinoma compared to when the same epithelia was combined with control stromal cells. Moreover, we found that the F β KO associated epithelia was refractile to androgen ablation. The mechanism of these observations seems to be due to stromally derived paracrine Wnt5a activating the epithelial frizzled receptor 2 that enabled prostate epithelial survival in an androgen deficient environment. We hope to gain permission to progress with these experiments to further address the mechanism of stromal TGF- β signaling impact on prostate cancer androgen responsiveness and differentiation.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	10	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover	
SF298	
Table of Contents	
Introduction	1
Body	2
Key Research Accomplishments	5
Reportable Outcomes	6
Conclusions	6
References	7

INTRODUCTION

The prostate epithelial and stromal compartments interact to regulate prostate development and function, in part through the tight regulation of glandular apoptosis and proliferation. These interactions are mediated by various factors that include hormones and cytokines. Specific signaling by androgens is required for prostate development and maintenance of function through the stimulation of proliferation and inhibition of apoptosis of prostatic epithelial cells (Hayward and Cunha, 2000; Montgomery et al., 2001). Cytokines such as EGF, IGF, and TGF- β isoforms can also in-turn stimulate the expression of the androgen receptor (AR) in an androgen-independent fashion (Byrne et al., 1996; Culig et al., 1996). Often the development and progression of prostate cancer is dependent on androgens and their receptor for prostate cellular proliferation and differentiation. As a result, its inhibition has been the primary therapy for metastatic prostate cancer and much effort has been devoted to elucidating the role of the androgen receptor in prostate cancer. As a result of androgen ablation TGF- β 1 expression levels transiently elevate and regression of benign prostate hyperplasia as well as prostate cancer cells for the most part occur. Better understanding of prostate androgen responsiveness is critical since androgen-signaling antagonists are currently used in treating patients with malignant prostate cancer, benign prostate hyperplasia, and as a chemoprevention of prostate cancer in clinical trials. However populations of hormone-non-responsive cancer cells unfortunately frequently arise. The **central hypothesis** of this proposal is that TGF- β signaling in the prostatic fibroblasts contributes to normal prostatic epithelial differentiation; when this signal is altered in the case of some cancers the differentiation status of the epithelia is altered.

TGF- β isoforms (TGF- β 1, β 2, β 3) have long been established as physiological regulators of prostate growth because of their ability to inhibit cell proliferation and mediate apoptosis (Kyprianou and Isaacs, 1989; Martikainen et al., 1990). TGF- β s exert their effects through binding to the TGF- β type II receptor (T β RII) and subsequent recruitment of the type I receptor (T β RI) for downstream cytoplasmic signaling through multiple parallel signaling pathways (Attisano and Wrana, 2002). TGF β plays a key role in the steroidal regulation of tissues and in the important growth regulation axis existing between androgenic signaling, smooth muscle differentiation and epithelial proliferation. The present proposal seeks to address the role of TGF β signaling in mouse prostate tissue under in vivo conditions in light of signaling pathways identified through studies in cell lines. In order to understand the role of TGF- β in the prostate we have developed and studied mouse models, that employ the Cre-lox methodology to conditionally ablate T β RII expression in the stromal fibroblasts (Bhowmick et al., 2004) and those that express the large SV40 T antigen transgene (TAG) in the prostate epithelia (from collaborator, Dr. Robert Matusik, Vanderbilt U., TN) (Kasper et al., 1998). The proposal was based on preliminary data that ablation of T β RII in fibroblasts results in preneoplastic prostate intraepithelial neoplasia (PIN) lesions and prostate-specific TAG expression results in PIN and progression of focal adenocarcinoma (Kasper et al., 1998). We proposed to develop mice that expressed both TAG in the prostate epithelia and concomitant loss of T β RII in the stromal fibroblasts (mouse model termed TNT) to examine epithelial and stromal differentiation (Task1). Since these TNT mice were not thought not to be able to live past 8 weeks of age, we also proposed to rescue the prostatic tissues from these mice as xenografts and further study differences in cellular differentiation and androgen responsiveness (Task2).

BODY

We focused on how the TGF β signaling pathway components may be involved in prostate cancer progression and subsequent regression. It was not feasible to study prostate cancer progression in the mouse model that expressed both TAG in the prostate epithelia and concomitant loss of T β R II in the stromal fibroblasts (mouse model termed TNT) due to early lethality (Task1). Previously, we developed the capacity to culture prostatic fibroblasts from wild type and F β KO (fibroblastic knockout for the TGF β receptor) mice. This allowed us to perform tissue recombinant xenografts where wild type epithelial cells were recombined with the two stromal cell types. We found that the combination of F β KO stromal cells with wild type epithelial cells resulted in the development of PIN lesions in (transformation) in the epithelial compartment with in 8 weeks of xenografting (**Figure 1**). The similar recombination with wild type stromal cells resulted in normal prostatic structures in the subrenal xenografts. These results suggest that the loss of stromal TGF β responsiveness results in the transformation of prostatic epithelia independent of other factors associated with the F β KO intact mice. Interestingly, prostates from F β KO mice do not seem to progress from PIN to prostate adenocarcinoma. Thus it was important to understand the role of TGF β signaling by the stromal cells in the context of epithelia mutations that can result in adenocarcinoma.




Figure 1. The conditional knockout of *Tgfbr2* through the targeting of Cre expression by the FSP1 promoter results in recombination of *Tgfbr2*^{lox/lox} in stromal fibroblasts through out the mouse. (A) Primary cultures of prostate epithelia and fibroblasts from *Tgfbr2*^{lox/lox} (Flox) and *Tgfbr2*^{fspKO} (KO) mice were affinity cross-linked with [¹²⁵I]-TGF- β 1 in the presence or absence of competing cold TGF- β 1. (B) The recombination of wild type epithelial organoids with either *Tgfbr2*^{lox/lox} or *Tgfbr2*^{fspKO} result in the prostatic glandular formation in subrenal xenografts. The *Tgfbr2*^{fspKO} stroma induced normal prostatic epithelia to form PIN like structures compared to those associated with *Tgfbr2*^{lox/lox} stromal cells. (C) Ki67 immunostaining suggest elevated proliferation of the prostatic epithelia associated with *Tgfbr2*^{fspKO} stromal cells.

The expression of the large T antigen by the prostatic epithelia, driven by the probasin promoter in transgenic mice, results in primarily in PIN lesions by 12-15 week of age with occasional foci of adenocarcinoma. Initial studies in recombining prostatic stromal cells from Flox and F β KO mice with the 12T7f epithelial organoids proved to be interesting. The recombined tissues were xenografted under the renal capsule for 8 weeks. After which time, some of the host mice were castrated. **Figure 2** shows the gross images of the tumor tissues from these experiments. Interestingly we found that the F β KO stroma resulted in smaller tumors, however the epithelia associated with the F β KO stromal cells were less differentiated than those associated with wild type stromal cells (**Figure 3**). The gross image in **Figure 2** also suggested F β KO stromal cells inhibited epithelial of regression upon castration. The staining for TUNEL provided indices for apoptosis following castration of the host mice (**Figure 4**). This phenotype is reminiscent of that observed in the F β KO mice. Thus together it would suggest that the stromal cells mediate the size and androgen responsivity of the prostate and well as prostate cancer.

Next we wanted to determine the mechanism for the phenotype observed with regard to the lack of regression following castration. In doing so we found that Wnt signaling was upregulated by the F β KO stroma compared to the Flox stroma *in vivo*. Through real time

Figure 2. Gross pictures of tissue recombinations of prostatic epithelial cells from LADYTAG mice with stromal cells from Flox (control) or F β KO mice 5 weeks. The lower panel shows regression of the tumor associated with the Flox stromal cells. The arrows indicate the xenograft within the renal capsule.




Figure 3. Tissue recombinants of Flox or FBKO stromal cells with epithelia expressing the large T antigen were xenografted for 9 weeks in SCID mice. The histology indicated less differentiated epithelia when associated with the FBKO stroma compared to the PIN like lesions when associated with Flox stromal cells. Androgen responsiveness of the grafts was determined by castration of the host mice for seven days. The resulting ducts associated with Flox stromal cells were appreciably smaller than those from the corresponding intact mice. The duct size of the FBKO associated grafts did not seem to change following castration. The left (200x) and right (400x) panels are indicate xenografts from hosts following castration (Cx) or intact (Int). See Figure 2 for gross images of the tissues shown here.





Figure 4. Apoptosis of the tumors were greater following castration when Flox stromal cells were used in contrast to when FBKO stromal cells were used. TUNEL staining (brown) of the xenografts shown in Figures 2 and 3 indicate apoptotic index of the tumors seven days following castration.

RT-PCR of prostates we found that there were elevated levels of Wnt5a expression intact FBKO prostates compared to age matched at 6 week control prostates of Flox mice (**Figure 5**). The Wnt5a-Frizzled receptor complex stimulates β -catenin stabilization and nuclear translocation coupled to TCF-4 (T cell factor). This transcription factor complex binds promoters of various genes that include those of c-myc and cyclinD1. The TCF/ β -catenin consensus binding sequence has been incorporated into an artificial reporter construct termed TOP by the Volegstein laboratory for assays in cultured cells (He et al., 1998). However, to better examine canonical Wnt signaling *in vivo*, a transgenic mouse termed TOPGal was developed by the Fuches laboratory with a similar TOP reporter driving the bacterial LacZ gene to allow visualization of promoter activity through β -galactosidase blue staining (DasGupta and Fuchs, 1999). Thus, to visualize TGF- β regulated paracrine Wnt activity in the prostate we crossed the FBKO mice with TOPGal mice. We further, examined canonical Wnt signal activation in the presence and absence of androgen signaling through castration experiments. We found that the Flox-TOPGal (control) mice did not exhibit β -galactosidase activity in the intact mice, but was active in a fraction of the prostatic luminal epithelial cells from days 3-5 following castration (**Figure 6**). Interestingly, there was no visible β -galactosidase activity 7 days following castration in Flox/TOPGal prostates (data not shown). In contrast, FBKO/TOPGal prostatic epithelia exhibited Wnt activity in intact mice and through the seven days following castration (**Figure 6**). These results were confirmed by examining Wnt5a expression in the stromal compartment of laser captured paraffin embedded prostatic tissues from intact and castrated Flox and FBKO mice (data not shown). The fact that only a fraction of the regressing Flox/TOPGal prostatic epithelia exhibited TOP activity, yet the entire non-regressing FBKO/TOPGal prostate have TOP activity suggest that Wnt signaling may be a survival signal.

These results lead us to suggest the hypothesis that localized TGF- β activation following androgen ablation is not in fact a direct signal for apoptosis, but rather a inhibitor of a survival signal mediated through epithelial




Figure 5. The expression of Wnt5a was determined by real time RT-PCR of prostates from Flox and FBKO mice. RNA was extracted from whole dorsolateral lobes from intact (0 day) or 3 days following castration. The amplified cDNA was measured by Syber Green fluorescence on a BioRad ICycler PCR machine..




Figure 6. Transgenic Flox/TOPGal (a) and FBKO/TOPGal (b) mice were developed by crossing the $Tgfr2^{fspko}$ and TOPGal mice. The prostates of these mice were incubated with X-gal substrate for visualization of Wnt signaling activation, interestingly only in the epithelial compartment of the FBKO/TOPGal prostates. Nuclear fast red was used as a counterstain. Asterisks indicate stromal cells in both panels.

canonical Wnt5a signaling. Thus we develop another model to rescue the lack of androgen responsiveness of the FBKO prostates. We chose to inhibit Wnt5a signaling by the frizzled receptor 2 through the expression of the secreted soluble domain of the frizzled receptor 2 (SFzR2) through adenoviral infection. We were unsuccessful in accomplishing this in intact mice, since the FBKO mice were too fragile for the multiple survival surgeries. Thus we harvested prostate tissue from Flox and FBKO mice, incubated with either GFP (control) or SFzR2 adenovirus, and rescued the tissue by xenografting under the renal capsule of syngenic male B1/6 mice. After 2 weeks the host mice were either castrated or left intact. **Figure 7** shows that FBKO prostates that were infected with SFzR2 adenovirus had increased apoptosis seven days following castration. In comparison GFP transduction did not seem to alter the apoptosis rate on either the Flox or FBKO prostate tissue from what observed in previous experiments where the intact mice were used (see original proposal). We will have a pathologist score the previously stained tissue sections for apoptosis and proliferation. The data will undergo biostatistical evaluation. These striking results of paracrine Wnt5a signaling regulating prostate regression is currently being written up for manuscript submission.




Figure 7. The intact prostates from the Flox and FBKO mice were rescued and xenografted under the renal capsule of syngenic B1/6 mice. At the time of xenografting, the tissues were either transduced with adenovirus for the expression of GFP (control) or soluble frizzled receptor 2 (SFzR2). Two weeks after xenografting the the host mice were androgen ablated through the castration and the grafts collected after seven days. TUNEL staining (brown nuclei) illustrates elevated apoptosis in FBKO following expression of SFzR2. This would suggest canonical Wnt signaling is important in the maintenance of prostatic epithelia following castration.

c. Significance: Surgery and androgen ablation therapy remains the major treatment for prostate cancer. However, within a year of treatment >80% of prostate cancer becomes androgen independent as a result of documented mutations in AR (50%) and unknown factors (50%). New treatments are required that are more effective irrespective of the structure of the AR in the cancerous epithelial cells. Based on our analysis of the *Tgfb β 2^{fspko}* mouse model, we believe that targeting therapy to the prostate stroma rather than the cancer cells may be prudent in patients' androgen non-responsive prostate cancer. The non-transformed stromal cells are likely to have greater genomic stability and are less likely to be subject of mutation adaptation since the target would be the secretion of paracrine factors that would act on the epithelia.

d. Plans: Presently, we have been able to maintain that schedule and we are making every attempt to complete all the tasks proposed.

KEY RESEARCH ACCOMPLISHMENTS

- We provide in vivo data supporting stromal TGF- β signaling can regulate prostate cancer androgen responsiveness in a tissue recombination model.
- We showed that *Wnt5a* is expressed by the prostatic stroma following androgen ablation in a short window.
- The activation of *Wnt5a* is regulated by TGF β responsiveness of the prostatic stroma
- Specific inhibition of the Frizzled receptor 2 in the epithelial compartment can result in regression of prostates that were otherwise refractile to androgen ablation.

REPORTABLE OUTCOMESResearch*Manuscripts*

None

Abstracts

- Placencio, V.R., Sharif-Afshar, A.-R., Simon W. Hayward, and **Bhowmick N.A.** (2005) Prostatic Epithelial Transformation and Androgen Responsiveness Regulated by Stromal-Epithelial Interactions. (oral presentation) Society For Basic Urologic Research Meeting. Miami, FL.

Awards received based on work supported by this grant

None

Products*CDNA construct, cell lines, and animal models developed*

- Development of a *in vivo* tissue recombination model that incorporates large T antigen expressing prostatic epithelia with stromal cells deficient in TGF β responsiveness.
- Transgenic mouse line termed F β KO/TOPGal that enables the study of canonical Wnt signaling in the context of stromal cells deficient for TGF β responsiveness.

CONCLUSION

The differentiation of the prostatic epithelium and stroma occur concurrently in an androgen-dependent mechanism. The concurrent loss of stromal TGF β responsiveness and development of PIN (through targeted expression of the large T antigen) can result in the undifferentiated adenocarcinoma. Further, the TGF- β signaling in the prostate stroma can dictate androgen responsiveness of the carcinoma cells. To examine the mechanism of these observations, we found that stromally derived paracrine Wnt5a mediates prostate epithelial survival in an androgen deficient environment.

REFERENCES

- Attisano, L., and Wrana, J. L. (2002). Signal transduction by the TGF-beta superfamily. *Science* 296, 1646-1647.
- Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., and Moses, H. L. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* 303, 848-851.
- Byrne, R. L., Leung, H., and Neal, D. E. (1996). Peptide growth factors in the prostate as mediators of stromal epithelial interaction. *Br J Urol* 77, 627-633.
- Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., and Klocker, H. (1996). Regulation of prostatic growth and function by peptide growth factors. *Prostate* 28, 392-405.
- DasGupta, R., and Fuchs, E. (1999). Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. *Development* 126, 4557-4568.
- Hayward, S. W., and Cunha, G. R. (2000). The prostate: development and physiology. *Radiol Clin North Am* 38, 1-14.
- He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998). Identification of c-MYC as a target of the APC pathway. *Science* 281, 1509-1512.
- Kasper, S., Sheppard, P. C., Yan, Y., Pettigrew, N., Borowsky, A. D., Prins, G. S., Dodd, J. G., Duckworth, M. L., and Matusik, R. J. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. *Lab Invest* 78, i-xv.
- Kyprianou, N., and Isaacs, J. T. (1989). Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. *Mol Endocrinol* 3, 1515-1522.
- Martikainen, P., Kyprianou, N., and Isaacs, J. T. (1990). Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. *Endocrinology* 127, 2963-2968.
- Montgomery, J. S., Price, D. K., and Figg, W. D. (2001). The androgen receptor gene and its influence on the development and progression of prostate cancer. *J Pathol* 195, 138-146.